BridgeBio Pharma Inc. (NASDAQ: BBIO) At $9.98 Is Worth A Gamble – Marketing Sentinel
Home  »  Technologies   »  BridgeBio Pharma Inc. (NASDAQ: BBIO) At $9.98 Is W...

BridgeBio Pharma Inc. (NASDAQ: BBIO) At $9.98 Is Worth A Gamble

During the last session, BridgeBio Pharma Inc. (NASDAQ:BBIO)’s traded shares were 5.6 million. At the end of the trading day, the stock’s price was $9.98, reflecting an intraday gain of 25.69% or $2.04. The 52-week high for the BBIO share is $57.44, that puts it down -475.55 from that peak though still a striking 50.1% gain since the share price plummeted to a 52-week low of $4.98. The company’s market capitalization is $1.72B, and the average intraday trading volume over the past 10 days was 3.07 million shares, and the average trade volume was 2.31 million shares over the past three months.

BridgeBio Pharma Inc. (NASDAQ:BBIO) trade information

BridgeBio Pharma Inc. (BBIO) registered a 25.69% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 25.69% in intraday trading to $9.98 this Thursday, 08/04/22, hitting a weekly high. The stock’s 5-day price performance is 9.43%, and it has moved by -5.85% in 30 days. Based on these gigs, the overall price performance for the year is -81.11%. The short interest in BridgeBio Pharma Inc. (NASDAQ:BBIO) is 20.9 million shares and it means that shorts have 10.01 day(s) to cover.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


BridgeBio Pharma Inc. (BBIO) estimates and forecasts

Statistics show that BridgeBio Pharma Inc. has outperformed its competitors in share price, compared to the industry in which it operates. BridgeBio Pharma Inc. (BBIO) shares have gone down -2.63% during the last six months, with a year-to-date growth rate more than the industry average at 0.77% against 0.20. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 4.50% this quarter and then jump 14.20% in the quarter after that. In the rating firms’ projections, revenue will decrease -33.00% compared to the previous financial year.

Revenue for the current quarter is expected to be $16.07 million as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to $9.03 million by the end of Sep 2022.

While earnings are projected to return -2.50% in 2022.

BBIO Dividends

BridgeBio Pharma Inc. is due to release its next quarterly earnings between February 23 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

BridgeBio Pharma Inc. (NASDAQ:BBIO)’s Major holders

BridgeBio Pharma Inc. insiders own 7.33% of total outstanding shares while institutional holders control 97.83%, with the float percentage being 105.57%. Kohlberg Kravis Roberts & Co. L.P. is the largest shareholder of the company, while 265 institutions own stock in it. As of Mar 30, 2022, the company held over 31.06 million shares (or 21.03% of all shares), a total value of $315.27 million in shares.

The next largest institutional holding, with 26.62 million shares, is of Viking Global Investors, L.P.’s that is approximately 18.02% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $270.2 million.

Also, the Mutual Funds coming in first place with the largest holdings of BridgeBio Pharma Inc. (BBIO) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Jun 29, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 8.5 million shares. This amounts to just over 5.75 percent of the company’s overall shares, with a $77.15 million market value. The same data shows that the other fund manager holds slightly less at 2.91 million, or about 1.97% of the stock, which is worth about $29.53 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts